Chinook Therapeutics Inc

NASDAQ:KDNY   3:59:53 PM EDT
13.10
-0.63 (-4.59%)
Products, Regulatory

Chinook Therapeutics Receives Orphan Drug Designation From European Commission For Atrasentan For Treatment Of Primary IgA Nephropathy

Published: 12/14/2021 14:08 GMT
Chinook Therapeutics Inc (KDNY) - Chinook Therapeutics Receives Orphan Drug Designation From European Commission for Atrasentan for Treatment of Primary Iga Nephropathy.
Chinook Therapeutics Inc - Expects to Present Data From Igan Patient Cohort of Phase 2 Affinity Study in First Half of 2022.
Chinook Therapeutics - Data From One Or More Additional Cohorts of Affinity Study Expected in Second Half of 2022.